

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

| | |
|-----------------------|------------------------------------|
| Name of entity | ZELIRA THERAPEUTICS LIMITED |
| ABN | 27 103 782 378 |

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

| | |
|----------------------------|----------------------------|
| Name of Director | Dr. Donna Gentile O'Donnel |
| Date of last notice | 1 June 2023 |

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

| | |
|--|---|
| Direct or indirect interest | Direct |
| Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest. | |
| Date of change | 24 November 2023 |
| No. of securities held prior to change | Nil |
| Class | Unquoted options |
| Number acquired | A. 10,000 - unlisted options expiring 24/11/2027 @ \$2.00 B. 10,000 - unlisted options expiring 24/11/2027 @ \$4.00 C. 10,000 - unlisted options expiring 24/11/2027 @ \$6.00 D. 10,000 - unlisted options expiring 24/11/2027 @ \$8.00 E. 10,000 - unlisted options expiring 24/11/2027 @ \$10.00 F. 95,000 - unlisted options expiring 24/11/2026 @ \$1.15 |
| Number disposed | |
| Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation | Non-cash as part of remuneration - \$91,430 |

+ See chapter 19 for defined terms.

Appendix 3Y Change of Director's Interest Notice

| | |
|---|---|
| No. of securities held after change | A. 10,000 - unlisted options expiring 24/11/2027 @ \$2.00 B. 10,000 - unlisted options expiring 24/11/2027 @ \$4.00 C. 10,000 - unlisted options expiring 24/11/2027 @ \$6.00 D. 10,000 - unlisted options expiring 24/11/2027 @ \$8.00 E. 10,000 - unlisted options expiring 24/11/2027 @ \$10.00 F. 95,000 - unlisted options expiring 24/11/2026 @ \$1.15 |
| Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back | Issue of options as approved by shareholders at the Company's AGM held 15 November 2023 |

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

| | |
|--|--|
| Detail of contract | |
| Nature of interest | |
| Name of registered holder (if issued securities) | |
| Date of change | |
| No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed | |
| Interest acquired | |
| Interest disposed | |
| Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation | |
| Interest after change | |

Part 3 – +Closed period

| | |
|--|-----|
| Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required? | N/A |
| If so, was prior written clearance provided to allow the trade to proceed during this period? | N/A |
| If prior written clearance was provided, on what date was this provided? | N/A |

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

| | |
|---|----------------|
| Name of entity ZELIRA THERAPEUTICS LIMITED | |
| ABN | 27 103 782 378 |

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

| | |
|----------------------------|-------------------|
| Name of Director | Greg Blake |
| Date of last notice | 11 September 2023 |

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

| | |
|---|--|
| Direct or indirect interest | Direct |
| Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small> | |
| Date of change | 24 November 2023 |
| No. of securities held prior to change | |
| Class | Unquoted options |
| Number acquired | A. 35,000 - unlisted options expiring 24/11/2027 @ \$2.00 B. 35,000 - unlisted options expiring 24/11/2027 @ \$4.00 C. 35,000 - unlisted options expiring 24/11/2027 @ \$6.00 D. 35,000 - unlisted options expiring 24/11/2027 @ \$8.00 E. 35,000 - unlisted options expiring 24/11/2027 @ \$10.00 |
| Number disposed | |
| Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small> | Non-cash as part of remuneration - \$82,836 |
| No. of securities held after change | A. 35,000 - unlisted options expiring 24/11/2027 @ \$2.00 B. 35,000 - unlisted options expiring 24/11/2027 @ \$4.00 C. 35,000 - unlisted options expiring 24/11/2027 @ \$6.00 D. 35,000 - unlisted options expiring 24/11/2027 @ \$8.00 E. 35,000 - unlisted options expiring 24/11/2027 @ \$10.00 |

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

| | |
|--|--|
| <p>Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</p> | <p>Issue of options as approved by shareholders at the Company's AGM held 15 November 2023</p> |
|--|--|

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

| | |
|---|--|
| Detail of contract | |
| Nature of interest | |
| Name of registered holder (if issued securities) | |
| Date of change | |
| <p>No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed</p> | |
| Interest acquired | |
| Interest disposed | |
| <p>Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation</p> | |
| Interest after change | |

Part 3 – +Closed period

| | |
|--|-----|
| Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required? | N/A |
| If so, was prior written clearance provided to allow the trade to proceed during this period? | N/A |
| If prior written clearance was provided, on what date was this provided? | N/A |

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

| | |
|---|----------------|
| Name of entity ZELIRA THERAPEUTICS LIMITED | |
| ABN | 27 103 782 378 |

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

| | |
|----------------------------|-----------------|
| Name of Director | Osagie Imasogie |
| Date of last notice | 3 February 2022 |

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

| | |
|---|--|
| Direct or indirect interest | Direct |
| Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small> | |
| Date of change | 24 November 2023 |
| No. of securities held prior to change | A. 428,883 ordinary shares B. 335,094 Class B performance rights |
| Class | Unquoted options |
| Number acquired | C. 30,000 - unlisted options expiring 24/11/2027 @ \$2.00 D. 30,000 - unlisted options expiring 24/11/2027 @ \$4.00 E. 30,000 - unlisted options expiring 24/11/2027 @ \$6.00 F. 30,000 - unlisted options expiring 24/11/2027 @ \$8.00 G. 30,000 - unlisted options expiring 24/11/2027 @ \$10.00 |
| Number disposed | |
| Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small> | Non-cash as part of remuneration - \$71,002 |

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

| | |
|---|---|
| No. of securities held after change | A. 428,883 ordinary shares B. 335,094 Class B performance rights C. 30,000 - unlisted options expiring 24/11/2027 @ \$2.00 D. 30,000 - unlisted options expiring 24/11/2027 @ \$4.00 E. 30,000 - unlisted options expiring 24/11/2027 @ \$6.00 F. 30,000 - unlisted options expiring 24/11/2027 @ \$8.00 G. 30,000 - unlisted options expiring 24/11/2027 @ \$10.00 |
| Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back | Issue of options as approved by shareholders at the Company's AGM held 15 November 2023 |

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

| | |
|--|--|
| Detail of contract | |
| Nature of interest | |
| Name of registered holder (if issued securities) | |
| Date of change | |
| No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed | |
| Interest acquired | |
| Interest disposed | |
| Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation | |
| Interest after change | |

Part 3 – +Closed period

| | |
|--|-----|
| Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required? | N/A |
| If so, was prior written clearance provided to allow the trade to proceed during this period? | N/A |

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

| | |
|---|-----|
| If prior written clearance was provided, on what date was this provided? | N/A |
|---|-----|

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

| | |
|---|----------------|
| Name of entity ZELIRA THERAPEUTICS LIMITED | |
| ABN | 27 103 782 378 |

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

| | |
|----------------------------|-----------------|
| Name of Director | Oludare Odumosu |
| Date of last notice | 11 August 2023 |

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

| | |
|---|--|
| Direct or indirect interest | Direct |
| Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small> | |
| Date of change | 24 November 2023 |
| No. of securities held prior to change (post 175:1 consolidation) | A. 131,766 ordinary shares B. 100,334 Class B performance rights |
| Class | Unquoted options |
| Number acquired | C. 40,000 - unlisted options expiring 24/11/2027 @ \$2.00 D. 40,000 - unlisted options expiring 24/11/2027 @ \$4.00 E. 40,000 - unlisted options expiring 24/11/2027 @ \$6.00 F. 40,000 - unlisted options expiring 24/11/2027 @ \$8.00 G. 40,000 - unlisted options expiring 24/11/2027 @ \$10.00 |
| Number disposed | |
| Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small> | Non-cash as part of remuneration - \$94,669 |

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

| | |
|--|--|
| No. of securities held after change | <p>A. 131,766 ordinary shares B. 100,334 Class B performance rights C. 40,000 - unlisted options expiring 24/11/2027 @ \$2.00 D. 40,000 - unlisted options expiring 24/11/2027 @ \$4.00 E. 40,000 - unlisted options expiring 24/11/2027 @ \$6.00 F. 40,000 - unlisted options expiring 24/11/2027 @ \$8.00 G. 40,000 - unlisted options expiring 24/11/2027 @ \$10.00</p> |
| Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small> | Issue of options as approved by shareholders at the Company's AGM held 15 November 2023 |

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

| | |
|---|--|
| Detail of contract | |
| Nature of interest | |
| Name of registered holder (if issued securities) | |
| Date of change | |
| No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small> | |
| Interest acquired | |
| Interest disposed | |
| Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small> | |
| Interest after change | |

Part 3 – ⁺Closed period

| | |
|---|-----|
| Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required? | N/A |
| If so, was prior written clearance provided to allow the trade to proceed during this period? | N/A |
| If prior written clearance was provided, on what date was this provided? | N/A |

⁺ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

| | |
|---|----------------|
| Name of entity ZELIRA THERAPEUTICS LIMITED | |
| ABN | 27 103 782 378 |

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

| | |
|----------------------------|-----------------|
| Name of Director | Timothy Slate |
| Date of last notice | 31 January 2022 |

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

| | |
|---|---|
| Direct or indirect interest | 1) Direct |
| Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small> | 2) T Slate Nominees Pty Ltd <Tim Slate Family A/C (Trustee and beneficiary) 3) Catalyst Corp Holdings Pty Ltd <Catalyst Investment A/C> (Trustee and beneficiary) |
| Date of change | 24 November 2023 |
| No. of securities held prior to change | 1) 206 Fully Paid Ordinary Shares 2) 7,675 Fully Paid Ordinary Shares |
| Class | Unquoted options |
| Number acquired | 2) A. 15,000 - unlisted options expiring 24/11/2027 @ \$2.00 B. 15,000 - unlisted options expiring 24/11/2027 @ \$4.00 C. 15,000 - unlisted options expiring 24/11/2027 @ \$6.00 D. 15,000 - unlisted options expiring 24/11/2027 @ \$8.00 E. 15,000 - unlisted options expiring 24/11/2027 @ \$10.00 3) A. 5,000 - unlisted options expiring 24/11/2027 @ \$2.00 B. 5,000 - unlisted options expiring 24/11/2027 @ \$4.00 C. 5,000 - unlisted options expiring 24/11/2027 @ \$6.00 D. 5,000 - unlisted options expiring 24/11/2027 @ \$8.00 E. 5,000 - unlisted options expiring 24/11/2027 @ \$10.00 |

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

| | |
|--|---|
| Number disposed | |
| Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small> | Non-cash as part of remuneration - \$47,335 |
| No. of securities held after change | 1) 206 Fully Paid Ordinary Shares 2) 7,675 Fully Paid Ordinary Shares A. 15,000 - unlisted options expiring 24/11/2027 @ \$2.00 B. 15,000 - unlisted options expiring 24/11/2027 @ \$4.00 C. 15,000 - unlisted options expiring 24/11/2027 @ \$6.00 D. 15,000 - unlisted options expiring 24/11/2027 @ \$8.00 E. 15,000 - unlisted options expiring 24/11/2027 @ \$10.00 3) A. 5,000 - unlisted options expiring 24/11/2027 @ \$2.00 B. 5,000 - unlisted options expiring 24/11/2027 @ \$4.00 C. 5,000 - unlisted options expiring 24/11/2027 @ \$6.00 D. 5,000 - unlisted options expiring 24/11/2027 @ \$8.00 E. 5,000 - unlisted options expiring 24/11/2027 @ \$10.00 |
| Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small> | Issue of options as approved by shareholders at the Company's AGM held 15 November 2023 |

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

| | |
|---|--|
| Detail of contract | |
| Nature of interest | |
| Name of registered holder (if issued securities) | |
| Date of change | |
| No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small> | |
| Interest acquired | |
| Interest disposed | |
| Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small> | |
| Interest after change | |

+ See chapter 19 for defined terms.

Part 3 – +Closed period

| | |
|--|-----|
| Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required? | N/A |
| If so, was prior written clearance provided to allow the trade to proceed during this period? | N/A |
| If prior written clearance was provided, on what date was this provided? | N/A |

+ See chapter 19 for defined terms.